A clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement
Open Access
- 19 April 2022
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 22 (1) , 1-6
Abstract
Objective: To explore the role of genetic testing of VKORC1 and CYP2C9 in determining the dosage of warfarin after aortic valve replacement. Methods: A total of 172 patients receiving warfarin after aortic valve replacement were divided into a control group (n = 86) and an experimental (n = 86) group based on acceptance of genetic testing. In the experimental group, three loci of VKORC1 and CYP2C9 were tested by polymerase chain reaction-restriction fragment length polymorphism technique, and the initial dose of warfarin was determined based on the genetic testing results and warfarin oral-dose table recommended by U.S. Food and Drug Administration (FDA). In the control group, warfarin (3 mg per night) was used as the initial dose. The international normalized ratio (INR) of each patient was continuously monitored after medication. The percentages of patients meeting the target INR in the two groups at specific time points and at 3-month follow-up after discharge from the hospital were monitored, and the incidence of various adverse events was compared between the groups. Results: Based on the results of genetic testing, 68 patients received 3–4 mg/d (79.1%), 10 patients received 0.5–2 mg/d (11.6%), and eight patients received 5–7 mg/d (9.3%) as the initial dosages of warfarin in the experimental group. The percentages of the patients meeting the target INR on the third and sixth day of postoperative medication were 45.3% and 73.3%, respectively, in the experimental group, and 29.8% and 58.3%, respectively, in the control group. The INR critical values during hospitalization occurred in 2.3% in the experimental group and in 7.1% in the control group, while the percentage of the patients meeting the target INR after 3 months was 86.1% in the experimental group and 83.1% in the control group. Conclusion: Genetic testing may guide the selection of the initial dose of warfarin after heart valve replacement to rapidly achieve a stable dose.Keywords
Funding Information
- National Natural Science Foundation of China (81871758)
This publication has 13 references indexed in Scilit:
- Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patientsJournal of International Medical Research, 2013
- Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: A systematic review and meta-analysisInternational Journal of Cardiology, 2013
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: A cross-sectional study in IranClinical Therapeutics, 2010
- Outcomes and predictors of very stable INR control during chronic anticoagulation therapyBlood, 2009
- Effect of VKORC1 –1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patientsThrombosis Research, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseBlood, 2008
- Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patientsEuropean Journal of Clinical Pharmacology, 2007
- Clinical consequences of cytochrome P450 2C9 polymorphismsClinical Pharmacology & Therapeutics, 2005